Narendranath Epperla
( out of 30 reviews )

Narendranath Epperla, MD, MS, FACP

  • Specialties

    Patient Rating

    4.9 /5
    ( out of 30 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    June 12, 2025
    HUNTSMAN CANCER CENTER

    Very nice easy to talk to talked to me in layman's terms so I could understand

    June 06, 2025
    HUNTSMAN CANCER CENTER

    Dr. Epperla is very Dr Epperla has a great way of explaining disease in a way that is easy to understand and makes a person feel confident of his skills.

    May 09, 2025
    HUNTSMAN CANCER CENTER

    Waited from 11.20 am until about 2pm. Delays happen but need to be planned for in the scheduled number of appointments. Was much too long and needed protein to eat

    May 01, 2025
    HUNTSMAN CANCER CENTER

    Very good information on my care

    February 28, 2025
    HUNTSMAN CANCER CENTER

    He is very competant.

    February 12, 2025
    HUNTSMAN CANCER CENTER

    He took the time needed to explain test results and plan of action for my health care. He is a very thoughtful doctor.

    February 12, 2025
    HUNTSMAN CANCER CENTER

    Dr. Epperla is a stud! He has been everything you would ask from your physician; very professional knowledgeable, kind, and extremely concerned about my on going mental and physical state during treatment. He takes the time to break down technical aspects of my treatment into understandable terms and walks me through what to expect. I will be forever indebted to him for his support and care.

    January 16, 2025
    HUNTSMAN CANCER CENTER

    He is an amazing doctor. He explains everything and old-fashioned words and drawings.

    December 19, 2024
    HUNTSMAN CANCER CENTER

    Very nice experience

  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor
    Academic Divisions Hematology & Hematologic Malignancies

    Selected Publications

    Journal Article

    1. Altomare NJ, Herr MM, Nair NM, Stephens DM, Cohen JB, Epperla N, Cortese M, Bhansali R, Moyo TK, V Kenkre, Ollila T, Hess B, Fitzgerald L, Shouse G, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin A, Ma S, Winter JN, Danilov A, Barta SK, Gordon LI, Romancik J, Grover NS and Karmali R (2025). Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART. Cancers, 17(14).
    2. Sharp J, Zhao Q, Voorhees TJ, Bond DA, Sawalha Y, Reneau J, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Brammer JE, Maddocks K, Christian B, Bezerra E, Denlinger N, Vasu S, De Lima M, Prosek J, Epperla N (2025). Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma. Br J Haematol. (Read full article)
    3. Sharp J, Shanaah AY, Voorhees TJ, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla N (2025). Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. J Natl Compr Canc Netw, 1-5. (Read full article)
    4. St-Pierre F, Bhatta S, Doukas PG, Jenkin M, Annunzio K, Rojek AE, Gibson A, Tiger YK, McCall B, Alhamad K, Hansen A, Alderuccio JP, Adewale O, Patel K, Trabolsi A, Lossos IS, Fitzgerald L, Ollila TA, Matasar MJ, Kline J, Karmali R, Epperla N (2025). Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study. Blood Cancer J, 15(1), 110. (Read full article)
    5. Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen L (2025). How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study. Future Oncol, 1-10. (Read full article)
    6. Borja-Montes OF, Bode A, Escobar-Gil T, Toro-Pedroza A, Epperla N, Andritsos LA (2025). Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years. EJHaem, 6(3), e70065. (Read full article)
    7. Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, Gergis U, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez JC (2025). Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. Bone Marrow Transplant.
    8. Torka P, Grover NS, Voorhees TJ, Karmali R, Annunzio K, Watkins MP, Anampa-Guzmn A, Reves H, Tavakkoli M, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla N (2025). Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study. Hematol Oncol, 43(3), e70087. (Read full article)
    9. Cappelli L, Kayne A, Newman J, Elguindy A, Epperla N, Palmer JD, Outschoorn UM, Porcu P, Shi W, Alnahhas I (2025). Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression. Neuro-oncology advances, 7(1), vdaf082.
    10. Cappelli L, Kayne A, Newman J, Elguindy A, Epperla N, Palmer JD, Outschoorn UM, Porcu P, Shi W, Alnahhas I (2025). Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression. Neurooncol Adv, 7(1), vdaf082. (Read full article)
    11. Karmali R, Shouse G, Torka P, Moyo TK, Romancik J, Barta SK, Bhansali R, Cohen JB, Shah NN, Zurko J, Kenkre VP, Hess B, Stephens DM, Fitzgerald L, Ollila T, Tabiti B, Roy I, Ma S, Winter J, Pro B, Moreira J, Danilov AV, David K, Gordon LI, Epperla N (2025). Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy. Blood Cancer J, 15(1), 43. (Read full article)
    12. Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Geethakumari PR, Hamadani M, Grover N, Epperla N (2025). Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers. Blood Cancer J, 15(1), 45. (Read full article)
    13. LeHanka AM, Kebede AM, Amirmokhtari N, Stanek JR, Willen F, Yeager N, Christian B, Epperla N, Sawalha Y, Sigmund AM, Brammer JE, Voorhees TJ, Reneau JC, Baiocchi RA, Maddocks KJ, Cairo MS, Audino AN, Bond DA (2025). Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Cancer Center. Pediatr Blood Cancer, 2025 Jun;72(6):e31664.
    14. Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC (2025). Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica, 110(3), 706-714. (Read full article)
    15. Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch RC, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared JA, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik AP, Hill BT, Kamdar M, Ortiz-Maldonado V, Martnez-Cibrian N, Shune L, Shadman M (2025). Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. Blood. (Read full article)
    16. Trabolsi A, Han S, Epperla N, Annunzio K, Baidoun F, Alhaj Moustafa M, Morgenstern-Kaplan D, Doukas P, St-Pierre F, McCall B, Fitzgerald L, Sandoval-Sus J, Dalal S, Reis IM, Chapman-Fredricks JR, Kim SH, Au C, Otto NB, Alhamad K, Ollila T, Karmali R, Shouse G, Lossos IS, Alderuccio JP (2024). Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study. Blood Neoplasia, 2(1), 100063. (Read full article)
    17. Vaughn JL, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N (2024). A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study. Blood Cancer J, 14(1), 212. (Read full article)
    18. Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen L (2024). Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood Cancer J, 14(1), 210. (Read full article)
    19. Aqeel SB, Faisal MS, Akhtar OS, Attwood K, George A, Advani P, Epperla N, Torka P (2024). Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis. Ann Hematol Oncol.
    20. Bajwa A, Zhao Q, Geer MJ, Lin C, Westholder J, Maakaron J, Ghosh M, Frame DG, Galal A, Tossey J, Ahmed N, Bezerra ED, Denlinger N, de Lima MJ, Epperla N, Caimi PF, Voorhees TJ (2024). Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Related CRS and ICANS - A Multicenter Retrospective Analysis. Blood Advances.
    21. Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman A, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi Y, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein P, Chaudhry A, Olszewski AJ (2024). High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Adv, 8(20), 5355-5364. (Read full article)
    22. Grover NS, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzmn A, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla N (2024). Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study. Blood Cancer J, 14(1), 182. (Read full article)
    23. Munir M, Sayed A, Addison D, Epperla N (2024). Cardiovascular Toxicities Associated with Novel Cellular Immune Therapies. Blood Adv. (Read full article)
    24. Bommier C, Link BK, Gysbers BJ, Maurer MJ, Larson MC, Khurana A, Wang Y, Thompson CA, Chihara D, Alderuccio JP, Koff JL, Epperla N, Conconi A, Lossos IS, Nowakowski GS, Feldman AL, Habermann TM, King RL, Cerhan JR (2024). Transformation in Marginal Zone Lymphoma: Results from a Prospective Cohort and a Meta-Analysis of the Literature. Blood Adv. (Read full article)
    25. Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, Kanakry JA, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed S (2024). Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis. Br J Haematol.
    26. Kapoor N, Zhao Q, Stiff A, Bhat SA, Anghelina MI, Andritsos LA, Blachly JS, Epperla N, Boghdadly ZE, Grever MR, Rogers KA (2024). Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia. . EJHaem.
    27. Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, Barta SK, Caimi PF, Sethi TK, Reddy N, Karmali R, Bello C, Chavez JC, Kothari SK, Hernandez-Ilizaliturri FJ, Svoboda J, Lansigan F, Glenn MJ, Cohen JB, Sorge C, Christian B, Herrera AF, Hamadani M, Costa LJ, Xavier AC (2024). Evaluation of prognostic factors for high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Adv. (Read full article)
    28. Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez A (2024). Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. Leukemia.
    29. Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz RM, Miao J, Song C, Wu D, Chan WK, Bezerra E, Epperla N, Voorhees TJ, Brammer J, Kittai AS, Bond DA, Sawalha Y, Sigmund A, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks K, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski S, Li Z, Huang X, Yang Y (2024). Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma. Blood Advances.
    30. Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo TK, Kenkre V, Ollila TA, Fitzgerald L, Hess B, David K, Roy I, Zurko J, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin I, Ma S, Moreira J, Winter J, Pro B, Stephens DM, Danilov A, Shah NN, Cohen JB, Barta SK, Torka P, Gordon LI (2024). Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv, 8(10), 2592-2599. (Read full article)
    31. Annunzio K, Bhatta S, Hanel W, Zhao Q, Owen M, Rosen H, Voorhees TJ, Bond DA, Sawalha Y, Sigmund AM, Alinari L, Baiocchi RA, Maddocks KJ, Jones D, Christian B, Epperla N (2024). Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients. Hematol Oncol.
    32. Sayed A, Munir M, Poliner M, Sughra S, Epperla N, Addison D (2024). Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi et al. J Immunother Cancer.
    33. Melody M, Epperla N, Shouse G, Romancik JT, Allen PB, Moyo TK, Kenkre VP, Ollila TA, Fitzgerald LA, Hess BT, David KA, Herr MM, Odetola O, Lin AY, Moreira J, Ma S, Winter JN, Roy I, Stephens DM, Danilov AV, Shah NN, Barta SK, Cortese MJ, Cohen J, Gordon LI, Karmali R (2024). Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy. Blood Adv. (Read full article)
    34. Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, Habib A, Kola-Kehinde O, Ruz P, Khan S, Sharma S, Meara A, Mahmood S, Feldman S, Yang EH, Kim J, Epperla N, Addison D (2024). Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer, 12(2). (Read full article)
    35. Epperla N, Zhao Q, Moyo T, Watkins MP, Tavakkoli M, Bello C, Torka P, Reddy N, Thomas C, Annunzio K, Christian B, Barta SK, Shouse G, Olszewski AJ, Bartlett NL (2023). Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. Blood Adv, 8(3), 549-552. (Read full article)
    36. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA (2023). Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood, 143(6), 496-506. (Read full article)
    37. Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan FT, Dholaria BR, Maakaron JE, Sandoval-Sus JD, Mishra R, Saha A, Annunzio K, Bhaskar ST, Sumransub N, Fijalka A, Ivanov SA, Lin Y, Kharfan-Dabaja MA (2023). Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplant, 59(2), 211-216. (Read full article)
    38. Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David K, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel S, Torka P, Lynch R, Smith S, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang P, Pinnix CC, Gunther JR, Dabaja BS, Lee HJ (2023). Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood Adv, 7(24), 7485-7493. (Read full article)
    39. Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzmn A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Ramakrishnan Geethakumari P, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla N (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood Adv, 7(22), 6839-6843. (Read full article)
    40. Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzman A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Geethakumari PR, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla N (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood Advances, (2023) 7 (22), 6839-6843.
    41. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ (2023). High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv, 7(21), 6381-6394. (Read full article)
    42. Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J (2023). Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv, 7(21), 6630-6638. (Read full article)
    43. Rezazadeh A, Szabo A, Khurana A, Inwards DJ, Lunning MA, Bartlett NL, Caimi PF, Rodgers TD, Barr PM, Chowdhury SM, Epperla N, Mendries H, Hill BT, Oh TS, Karmali R, Chang JE, Goyal G, Parsons BM, Isaac KM, Portell CA, Monahan K, Siker M, King DM, Fenske TS (2023). Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study. Haematologica. (Read full article)
    44. Dhir A, Epperla N, Costa LJ, Xavier AC (2023). Nonbiological factors affecting outcomes in adolescents and young adults with lymphoma. Front Public Health, 11, 1261066. (Read full article)
    45. Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal L (2023). Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia, 37(10), 2094-2106. (Read full article)
    46. Nalin A, Zhao Q, Voorhees T, Bond D, Sawalha Y, Hanel W, Sigmund A, Annunzio K, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla N (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia. Front Oncol, 13, 1264387. (Read full article)
    47. Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzmn A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, Olszewski AJ (2023). Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood Adv, 7(17), 5038-5046. (Read full article)
    48. Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M (2023). ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther, 29(9), 548-555. (Read full article)
    49. McKenna M, Epperla N, Ghobadi A, Liu J, Lazaryan A, Ibrahim U, Jacobson CA, Naik SG, Nastoupil L, Chowdhury SM, Voorhees TJ, Jacobs MT, Farooq U, Osman K, Olszewski AJ, Ahmed S, Evens AM (2023). Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. Br J Haematol, 202(2), 248-255. (Read full article)
    50. Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali R (2022). Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv, 7(12), 2657-2669. (Read full article)
    51. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB (2022). Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv, 7(11), 2287-2296. (Read full article)
    52. David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Chang J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM (2023). Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol, 98(6), 900-912. (Read full article)
    53. Annunzio K, Cackovic M, Bond D, Sawalha Y, Voorhees TJ, Hanel W, Alinari L, Baiocchi R, Reneau J, Brammer J, Maddocks K, Christian B, Epperla N (2022). Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy. Blood Adv, 7(10), 2241-2244. (Read full article)
    54. Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin P (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma, 64(5), 1026-1034. (Read full article)
    55. Faisal MS, Hanel W, Voorhees T, Li R, Huang Y, Khan A, Bond D, Sawalha Y, Reneau J, Alinari L, Baiocchi R, Christian B, Maddocks K, Efebera Y, Penza S, Saad A, Brammer J, DeLima M, Jaglowski S, Epperla N (2023). Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Med, 12(7), 8228-8237. (Read full article)
    56. Azar JH, Evans JP, Sikorski MH, Chakravarthy KB, McKenney S, Carmody I, Zeng C, Teodorescu R, Song NJ, Hamon JL, Bucci D, Velegraki M, Bolyard C, Weller KP, Reisinger SA, Bhat SA, Maddocks KJ, Denlinger N, Epperla N, Gumina RJ, Vlasova AN, Oltz EM, Saif LJ, Chung D, Woyach JA, Shields PG, Liu SL, Li Z, Rubinstein MP (2023). Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. JCI Insight, 8(6). (Read full article)
    57. Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L (2023). A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. Cancers (Basel), 15(5). (Read full article)
    58. Epperla N, Reljic T, Chowdhury SM, Ferreri AJM, Kumar A, Hamadani M (2022). Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis. Hematol Oncol, 41(1), 88-96. (Read full article)
    59. Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G (2022). Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Adv, 7(1), 88-91. (Read full article)
    60. Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wrmann B, Rai K, Grever M (2022). Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J, 12(12), 165. (Read full article)
    61. Andritsos LA, Anghelina M, Neal J, Blachly JS, Mathur P, Lele O, Dearden C, Iyengar S, Cross M, Zent CS, Rogers KA, Epperla N, Lozanski G, Oakes CC, Kraut E, Ruppert AS, Zhao Q, Bhat SA, Forconi F, Banerji V, Handunnetti S, Tam CS, Seymour JF, Else M, Kreitman RJ, Saven A, Call T, Parikh SA, Ravandi F, Johnston JB, Tiacci E, Troussard X, Tallman MS, Dietrich S, Tadmor T, Gozzetti A, Zinzani PL, Robak T, Quest G, Demeter J, Rai K, Fernandez SA, Grever M (2022). Development of a distributed international patient data registry for hairy cell leukemia. Leuk Lymphoma, 63(13), 3021-3031. (Read full article)
    62. Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA (2022). Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia. Leuk Res, 120, 106919. (Read full article)
    63. Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi RA, Maddocks K, Sawalha Y (2022). Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study. Ther Adv Hematol, 13, 20406207221112900. (Read full article)
    64. Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A (2022). Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant, 57(7), 1150-1163. (Read full article)
    65. Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A (2021). Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplant Cell Ther, 28(6), 335.e1-335.e17. (Read full article)
    66. Voorhees TJ, Epperla N (2022). Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach. Expert Rev Anticancer Ther, 22(5), 523-533. (Read full article)
    67. Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, Olszewski AJ, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos IS (2021). An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv, 6(7), 2035-2044. (Read full article)
    68. Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N (2021). Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematol Oncol, 40(1), 48-56. (Read full article)
    69. Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian BA, Baiocchi RA, Maddocks K, Sawalha Y (2021). Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas. Blood Adv, 6(2), 460-472. (Read full article)
    70. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB (2021). Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv, 5(23), 5179-5189. (Read full article)
    71. Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM (2021). Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. Br J Haematol, 195(5), 757-763. (Read full article)
    72. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB (2021). Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol, 96(11), 1374-1384. (Read full article)
    73. DAngelo CR, Hanel W, Chen Y, Yu M, Yang D, Guo L, Karmali R, Burkart M, Ciccosanti C, David K, Risch Z, Murga-Zamalloa C, Devata S, Wilcox R, Savani M, Courville EL, Bachanova V, Rabinovich E, Peace D, Osman F, Epperla N, Kenkre VP (2021). Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. Hematol Oncol, 39(4), 473-482. (Read full article)
    74. Vaughn JL, Soroka O, Epperla N, Safford M, Pinheiro LC (2021). Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States. Cancer Med, 10(20), 7330-7338. (Read full article)
    75. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB (2021). Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. Eur J Haematol, 107(3), 301-310. (Read full article)
    76. Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, DAngelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ (2021). Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica, 106(7), 1932-1942. (Read full article)
    77. Vaughn JL, Spies D, Xavier AC, Epperla N (2021). Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States. Am J Hematol, 96(7), 816-822. (Read full article)
    78. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS (2021). Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol, 7(7), 993-1003. (Read full article)
    79. Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA (2021). Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res, 27(12), 3339-3350. (Read full article)
    80. Choueiry F, Singh S, Sircar A, Laliotis G, Sun X, Chavdoula E, Zhang S, Helmig-Mason J, Hart A, Epperla N, Tsichlis P, Baiocchi R, Alinari L, Zhu J, Sehgal L (2021). Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. Cancers (Basel), 13(9). (Read full article)
    81. Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens AM (2021). Burkitt Lymphoma International Prognostic Index. J Clin Oncol, 39(10), 1129-1138. (Read full article)
    82. Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, DAngelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP (2020). Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood, 137(3), 374-386. (Read full article)
    83. Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M (2020). Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transplant Cell Ther, 27(1), 58-66. (Read full article)
    84. Thangavadivel S, Zhao Q, Epperla N, Rike L, Mo X, Badawi M, Bystry DM, Phelps MA, Andritsos LA, Rogers KA, Jones J, Woyach JA, Byrd JC, Awan FT (2020). Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clin Cancer Res, 26(23), 6187-6195. (Read full article)
    85. Epperla N (2020). What is the optimal reduced-intensity conditioning regimen for patients with classical Hodgkin lymphoma undergoing allogeneic transplantation? - is there a one to use or avoid. Br J Haematol, 190(4), 490-492. (Read full article)
    86. Epperla N, Vaughn JL, Othus M, Hallack A, Costa LJ (2020). Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab? Cancer Med, 9(15), 5519-5525. (Read full article)
    87. Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M (2020). Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA Oncol, 6(7), 1011-1018. (Read full article)
    88. Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M (2020). Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol, 189(6), 1171-1181. (Read full article)
    89. Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M (2020). Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 126(10), 2279-2287. (Read full article)
    90. Palmer JD, Bhamidipati D, Shukla G, Epperla N, Glass J, Kim L, Shi W (2020). Outcomes after stereotactic radiosurgery for CNS lymphoma. J Neurooncol, 147(2), 465-476. (Read full article)
    91. Epperla N, Pavilack M, Olufade T, Bashyal R, Li J, Kabadi SM, Yuce H, Andritsos L (2020). Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis. Orphanet J Rare Dis, 15(1), 47. (Read full article)
    92. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS (2019). Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv, 4(1), 47-54. (Read full article)
    93. Epperla N, Hamadani M, Reljic T, Kharfan-Dabaja MA, Savani BN, Kumar A (2019). Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. Cancer, 125(24), 4417-4425. (Read full article)
    94. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS (2019). Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv, 3(11), 1661-1669. (Read full article)
    95. Guo S, Jiang S, Epperla N, Ma Y, Maadooliat M, Ye Z, Olson B, Wang M, Kitchner T, Joyce J, An P, Wang F, Strenn R, Mazza JJ, Meece JK, Wu W, Jin L, Smith JA, Wang J, Schrodi SJ (2019). A gene-based recessive diplotype exome scan discovers FGF6, a novel hepcidin-regulating iron-metabolism gene. Blood, 133(17), 1888-1898. (Read full article)
    96. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ (2018). Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leuk Lymphoma, 60(4), 940-946. (Read full article)
    97. Epperla N, Shanaah AY, Jones D, Christian BA, Ayyappan S, Maddocks K, Woyach JA (2018). Resistance mechanism for ibrutinib in marginal zone lymphoma. Blood Adv, 3(4), 500-502. (Read full article)
    98. Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N (2018). Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk, 19(2), 95-102. (Read full article)
    99. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M (2019). Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol, 12(1), 6. (Read full article)
    100. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB (2018). Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leuk Lymphoma, 59(12), 2862-2870. (Read full article)
    101. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB (2018). Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer, 124(11), 2306-2315. (Read full article)
    102. Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V (2018). Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 24(5), 983-988. (Read full article)
    103. Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaos-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, DSouza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M (2018). Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv, 2(8), 933-940. (Read full article)
    104. Xavier AC, Epperla N, Taub JW, Costa LJ (2017). Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. Am J Hematol, 93(2), 238-245. (Read full article)
    105. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J (2017). R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol, 180(4), 534-544. (Read full article)
    106. Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M (2017). Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant, 24(1), 78-85. (Read full article)
    107. Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS (2017). Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Hematol Oncol, 35(4), 528-535. (Read full article)
    108. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ (2017). C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer, 123(22), 4411-4418. (Read full article)
    109. Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB (2017). Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion, 57(11), 2775-2781. (Read full article)
    110. Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE (2017). Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. Br J Haematol, 178(3), 427-433. (Read full article)
    111. Dang G, Epperla N, Muppidi V, Sahr N, Pan A, Simpson P, Baumann Kreuziger L (2016). Medical Management of Pump-Related Thrombosis in Patients with Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis. ASAIO J, 63(4), 373-385. (Read full article)
    112. Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS (2017). Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk, 17(7), 408-414. (Read full article)
    113. Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M (2017). Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. J Hematol Oncol, 10(1), 117. (Read full article)
    114. Epperla N, Ye F, Idris A, Sakkalaek A, Liang H, Chyou PH, Dart RA, Mazza J, Yale S (2017). Treatment-Related Cardiovascular Outcomes in Patients with Symptomatic Subclavian Artery Stenosis. Cureus, 9(5), e1262. (Read full article)
    115. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, DSouza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M (2017). Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk, 17(5), 305-311.e2. (Read full article)
    116. Strouse C, Epperla N (2016). A rash diagnosis: Gemcitabine-associated pseudocellulitis. J Oncol Pharm Pract, 23(2), 157-160. (Read full article)
    117. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M (2016). Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. Am J Hematol, 92(2), 161-170. (Read full article)
    118. Raj RV, Hari P, Pasquini M, Epperla N, DSouza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M (2016). Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. Bone Marrow Transplant, 51(12), 1602-1604. (Read full article)
    119. Epperla N, Olteanu H, Hamadani M (2016). Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. Br J Haematol, 175(5), 758. (Read full article)
    120. Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS (2016). Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk, 16(12), 672-678. (Read full article)
    121. Epperla N, Harrington AM, Hemauer K, Shah NN (2016). Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. Am J Hematol, 91(11), 1161-1164. (Read full article)
    122. Epperla N, Weissman DE (2016). Chemotherapy: Response and Survival Data #99. J Palliat Med, 19(9), 1011. (Read full article)
    123. Epperla N, Strouse C, VanSandt AM, Foy P (2016). Difficult to swallow: warm autoimmune hemolytic anemia in a Jehovah's Witness treated with hemoglobin concentrate complicated by achalasia. Transfusion, 56(7), 1801-6. (Read full article)
    124. Epperla N, George B (2015). An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. J Gastrointest Cancer, 47(2), 206-9. (Read full article)
    125. Epperla N, Hemauer K, Friedman KD, George JN, Foy P (2015). Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. Am J Hematol, 91(6), 644-6. (Read full article)
    126. Jayarangaiah A, Epperla N (2015). Early recognition is the key to success: pulseless electrical activity (PEA) as a manifestation of heparin-induced anaphylactoid reaction. BMJ Case Rep, 2015. (Read full article)
    127. Epperla N, McKiernan F (2015). Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. Springerplus, 4, 455. (Read full article)
    128. Epperla N, Pathak R (2015). Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level. WMJ, 114(4), 163-6; quiz 167. (Read full article)
    129. Epperla N, Kattamanchi S, Fritsche TR (2014). Appearances are Deceptive: Staphylococcus Superinfection of Clavicular Tuberculous Osteomyelitis. Clin Med Res, 13(2), 85-8. (Read full article)
    130. Epperla N, Peterson E, Foy P (2015). An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. BMC Hematol, 15, 7. (Read full article)
    131. Epperla N, Hocking W (2014). Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res, 13(1), 32-5. (Read full article)
    132. Epperla N, Usoltseva N (2014). Unprovoked deep venous thrombosis in a young adult associated with membranous obstruction of inferior vena cava. BMJ Case Rep, 2014. (Read full article)
    133. Epperla N, Medina-Flores R, Mazza JJ, Yale SH (2015). Mirtazapine and mefloquine therapy for non-AIDS-related progressive multifocal leukoencephalopathy. WMJ, 113(6), 242-5. (Read full article)
    134. Epperla N, Landeck J, Sabbagh S (2015). Osmotic demyelination syndrome. WMJ, 113(5), 197-8. (Read full article)
    135. Epperla N, McKiernan FE (2014). An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis. Skeletal Radiol, 43(9), 1313-8. (Read full article)
    136. Epperla N, McKiernan FE, Kenney CV (2013). Radiographic findings in Waldenström's macroglobulinemia resembling fibrogenesis imperfecta ossium (FIO): a case report. Skeletal Radiol, 43(3), 381-5. (Read full article)
    137. Epperla N, Brilliant MH, Vidaillet H (2014). Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. BMJ Case Rep, 2014. (Read full article)
    138. Kasirye Y, Simpson M, Mamillapalli CK, Epperla N, Liang H, Yale SH (2014). Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. WMJ, 112(6), 244-9; quiz 250. (Read full article)
    139. Wagner BP, Epperla N, Medina-Flores R (2013). Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report. Diagn Pathol, 8, 192. (Read full article)
    140. Bapani S, Epperla N, Kasirye Y, Mercier R, Garcia-Montilla R (2012). ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole. Clin Med Res, 11(2), 86-90. (Read full article)
    141. Kasirye Y, Epperla N, Manne JR, Bapani S, Garcia-Montilla RJ (2012). Brain abscesses complicating acute pneumococcal meningitis during etanercept therapy. Clin Med Res, 10(4), 230-5. (Read full article)
    142. Kasirye Y, Manne JR, Epperla N, Bapani S, Garcia-Montilla R (2011). Apical hypertrophic cardiomyopathy presenting as recurrent unexplained syncope. Clin Med Res, 10(1), 26-31. (Read full article)
    143. Kasirye Y, Danhof RS, Epperla N, Garcia-Montilla RJ (2011). Sweet's syndrome: one disease, multiple faces. Clin Med Res, 9(3-4), 134-6. (Read full article)

    Review

    1. Bock AM, Epperla N (2025). Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. [Review]. J Hematol Oncol, 18(1), 68. (Read full article)
    2. Shelley CS, Galigue-Zouitina S, Andritsos LA, Epperla N, Troussard X (2024). The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease. [Review]. Leuk Lymphoma, 1-19. (Read full article)
    3. Jain N, Mamgain M, Chowdhury SM, Jindal U, Sharma I, Sehgal L, Epperla N (2023). Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents. [Review]. J Hematol Oncol, 16(1), 99. (Read full article)
    4. Hanel W, Herrera AF, Epperla N (2022). Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. [Review]. Exp Hematol Oncol, 11(1), 108. (Read full article)
    5. Epperla N, Hamadani M (2021). Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. [Review]. Hematology Am Soc Hematol Educ Program, 2021(1), 247-253. (Read full article)
    6. Epperla N, Herrera AF (2020). How I incorporate novel agents into the treatment of classical Hodgkin lymphoma. [Review]. Blood, 138(7), 520-530. (Read full article)
    7. Hanel W, Epperla N (2021). Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. [Review]. J Hematol Oncol, 14(1), 104. (Read full article)
    8. Liu Q, Harris N, Epperla N, Andritsos LA (2021). Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. [Review]. Onco Targets Ther, 14, 1797-1805. (Read full article)
    9. Epperla N, Hamadani M (2021). A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. [Review]. Curr Hematol Malig Rep, 16(1), 19-24. (Read full article)
    10. Hanel W, Epperla N (2020). Emerging therapies in mantle cell lymphoma. [Review]. J Hematol Oncol, 13(1), 79. (Read full article)
    11. Sircar A, Chowdhury SM, Hart A, Bell WC, Singh S, Sehgal L, Epperla N (2020). Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. [Review]. Int J Mol Sci, 21(3). (Read full article)
    12. Denlinger NM, Epperla N, William BM (2018). Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. [Review]. Cancer Manag Res, 10, 615-624. (Read full article)
    13. Epperla N, Hamadani M (2017). Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. [Review]. Hematol Oncol Stem Cell Ther, 10(4), 277-284. (Read full article)
    14. Epperla N, Fenske TS, Lazarus HM, Hamadani M (2015). Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? [Review]. Bone Marrow Transplant, 50(11), 1393-404. (Read full article)
    15. Epperla N, Fenske TS, Hari PN, Hamadani M (2015). Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. [Review]. World J Transplant, 5(3), 81-8. (Read full article)
    16. Epperla N, Mazza JJ, Yale SH (2016). A Review of Clinical Signs Related to Ecchymosis. [Review]. WMJ, 114(2), 61-5. (Read full article)
    17. Jayarangaiah A, Sehgal R, Epperla N (2014). Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature. [Review]. BMC Neurol, 14, 200. (Read full article)
    18. Manne JR, Kasirye Y, Epperla N, Garcia-Montilla RJ (2011). Non-cardiogenic pulmonary edema complicating electroconvulsive therapy: short review of the pathophysiology and diagnostic approach. [Review]. Clin Med Res, 10(3), 131-6. (Read full article)

    Book Chapter

    1. Walter H, Epperla N (2025). Hepatosplenic T-cell Lymphoma. In D.A. Sallman, A. Chaudhury, H. Saeed, L Zhang (Eds.), Handbook of Hematological Malignancies (3rd Edition, p. 491). Demos Medical Publishers.
    2. Epperla N, Hanel W, Talpaz M (2022). Cytokines, Interferons and Hematopoietic Growth Factors. In Cancer Medicine (10th Edition). John Wiley & Sons Inc.
    3. Epperla N, Herrera AF, Mei M (2022). Hematopoietic cell transplantation in classical Hodgkin lymphoma. In Cancer Consult (2nd Edition). John Wiley & Sons Inc.
    4. Epperla N, Jayarangaiah A, Fenske TS (2017). Hepatosplenic T-cell Lymphoma. In Sallman DA, et al (Eds.), Handbook of Hematologic Malignancies. Demos Medical Publishers.
    5. Epperla N, Atallah E (2017). Langerhans cell Histiocytosis and Histiocytic Sarcoma. In Sallman DA, et al (Eds.), Handbook of Hematologic Malignancies. Demos Medical Publishers.
    6. Epperla N, Fenske TS (2017). Mantle Cell Lymphoma. In Hari P, Abutalib S (Eds.), Clinical Manual of Blood & Marrow Hematopoietic Cell Transplantation. Wiley Blackwell Publishers.
    7. Epperla N, Hashmi H, Hamadani M (2017). Indolent Lymphomas. In Hari P, Abutalib S (Eds.), Clinical Manual of Blood & Marrow Hematopoietic Cell Transplantation. Wiley Blackwell Publishers.
    8. Schneidewend R, Epperla N, Friedman K (2017). Thrombotic Thrombocytopenia Purpura and the Hemolytic Uremic Syndrome. In Hoffman R, Benz EJ, Silberstein LE, Heslop H, Weitz J, Anastasi J (Eds.), Hematology: Basic Principles and Practice (7th Edition). Elsevier Publishers.
    9. Epperla N, Hamadani M, Horowitz MM (2017). Establishing a Hematopoietic Stem Cell Transplantation Unit: A Practical Guide. In Gluckman E, Niederwieser D, Aljurf M (Eds.), Indications for Allogeneic Hematopoietic Cell Transplantation in Adults. Springer Nature.

    Commentary

    1. Upshaw JN, Parson SK, Buchsbaum RJ, Schlam I, Ruddy KJ, Durani U, Epperla N, Leong DP (2024). Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines: JACC: CardioOncology Controversies in Cardio-Oncology. JACC CardioOncol.

    Editorial

    1. Hanel W, Epperla N (2023). Another step toward frontline BTK inhibitor therapy in MCL. Blood Adv, 7(23), 7358-7360. (Read full article)
    2. Qian L, De Lima M, Mims AS, Epperla N (2022). Editorial: Rising Stars in Hematologic Malignancies 2021. Front Oncol, 12, 858564. (Read full article)

    Letter

    1. Borja-Montes OF, Toro-Pedroza A, Epperla N, Andritsos LA (2025). Hairy cell leukaemia and pregnancy: A systematic review and review of literature. [Letter to the editor]. Br J Haematol. (Read full article)
    2. Epperla N, Shouse G, Grover NS, Torka P, Annunzio K, Watkins M, Anampa-Guzmn A, Christian B, Thomas C, Barta SK, Geethakumari PR, Karmali R, Bartlett NL, Olszewski AJ (2025). Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study. [Letter to the editor]. Exp Hematol Oncol, 14(1), 73. (Read full article)
    3. Vaughn JL, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N (2025). Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States. [Letter to the editor]. Biomark Res, 13(1), 64. (Read full article)
    4. Umyarova E, Pei C, Pellegrino W, Zhao Q, Sharma N, Benson D, Cottini F, Bezerra E, Brammer J, Bumma N, Choe H, Denlinger N, Devarakonda S, Khan A, Penza S, Rosko A, Vasu S, Wall S, Alinari L, Baiocchi R, Bond DA, Christian B, Hanel W, Maddocks K, Reneau J, Sawalha Y, Habib A, Sigmund A, Voorhees TJ, de Lima M, Epperla N (2025). Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies. [Letter to the editor]. J Hematol Oncol, 18(1), 30. (Read full article)
    5. Epperla N, Nastoupil LJ, Feinberg B, Galvin J, Pathak P, Amoloja T, Gentile D, Saverno K (2025). Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. [Letter to the editor]. Biomark Res, 13(1), 18. (Read full article)
    6. Chowdhury SM, Bhatta S, Voorhees TJ, Annunzio K, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Christian B, Jones D, Epperla N (2025). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma. [Letter to the editor]. J Hematol Oncol, 18(1), 4. (Read full article)
    7. Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Wrmann B, Zent CS, Zenz T, Zinzani PL (2024). Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms. [Letter to the editor]. Leukemia.
    8. Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R (2023). Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. [Letter to the editor]. J Hematol Oncol, 16(1), 111. (Read full article)
    9. Vaughn JL, Epperla N (2023). Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study. [Letter to the editor]. Biomark Res, 11(1), 84. (Read full article)
    10. Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, Anampa-Guzmn A, Oh TS, Reaves H, Tavakkoli M, Lindsey K, Greenwell IB, Hansinger E, Thomas C, Chowdhury SM, Annunzio K, Christian B, Barta SK, Geethakumari PR, Bartlett NL, Herrera AF, Grover NS, Olszewski AJ (2023). Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. [Letter to the editor]. J Hematol Oncol, 16(1), 49. (Read full article)
    11. Epperla N, Zhao Q, Anghelina M, Neal J, Blachly JS, Rogers KA, Lozanski G, Oakes CC, Bhat SA, Zent CS, Banerji V, Grever M, Andritsos LA (2023). Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis. [Letter to the editor]. Am J Hematol, 98(5), E116-E118. (Read full article)
    12. Vaughn JL, Gundepalli SG, Epperla N (2022). Racial differences in the survival of mantle cell lymphoma patients in the United States. [Letter to the editor]. Hematol Oncol, 40(3), 479-481. (Read full article)
    13. Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G (2022). Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. [Letter to the editor]. J Hematol Oncol, 15(1), 96. (Read full article)
    14. Vaughn JL, Pinheiro LC, Olszewski A, Epperla N (2021). Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). [Letter to the editor]. Am J Hematol, 96(4), E123-E126. (Read full article)
    15. Vaughn JL, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, William B, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Benson D, Devine S, Cataland S, Vasu S (2018). Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease? [Letter to the editor]. Bone Marrow Transplant, 54(6), 913-916. (Read full article)
    16. Epperla N, Kleman A, Karafin M, Foy P (2018). Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better? [Letter to the editor]. Ann Hematol, 97(9), 1727-1729. (Read full article)
    17. Epperla N, Hamadani M, Fenske TS, Costa LJ (2017). Incidence and survival trends in mantle cell lymphoma. [Letter to the editor]. Br J Haematol, 181(5), 703-706. (Read full article)
    18. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN (2017). Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. [Letter to the editor]. Am J Hematol, 92(10), E610-E611. (Read full article)
    19. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M (2016). Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. [Letter to the editor]. Bone Marrow Transplant, 52(1), 147-150. (Read full article)
    20. Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P (2016). Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. [Letter to the editor]. Am J Hematol, 91(6), E313-4. (Read full article)
    21. Hebbring SJ, Slager SL, Epperla N, Mazza JJ, Ye Z, Zhou Z, Achenbach SJ, Vasco DA, Call TG, Rabe KG, Kay NE, Caporaso NE, Lanasa MC, Camp NJ, Strom SS, Goldin LR, Cerhan JR, Brilliant MH, Schrodi SJ (2013). Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. [Letter to the editor]. Blood, 121(1), 237-8. (Read full article)

    Abstract

    1. S K Thiruvengadam, L Chen, S Ahmed, A Bock, N Epperla, S Godbole, Y Sawalha, A Jallouk, S Bhaskar, L Falchi, G Salles, M Lunning, J Crombie, R Merryman, A A Ayers, C Goth, G Shouse, C Flowers, A Danilov, A F Herrera, A Chauhan (2025). 161 | Outcomes Of Glofitamab And Epcoritamab In R/R Dlbcl Elderly Patients: A Real‐World Evidence Study From The Cubic Consortium. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025 [Abstract]. 43(S3).
    2. D Baggio, S Han, P Ghione, I Okcu, J Okosun, M Kamdar, A Kuhnl, N Grover, H Cherng, A Olszewski, P Ramakrishnan Geethakumari, J Smith, A Prica, J Khwaja, W Osborne, J Koff, D El-Sharkawi, N Wagner-Johnston, J Munoz, A Desai, N Epperla, F Baidoun, T Moyo, M Narkhede, A Barrett, K Linton, D Wallace, N Elmusharaf, J Sandoval-Sus, A Danilov, J Rhodes, A Santarsieri, F Karim, J Calabrese De Feo, R Tavarozzi, I Nizamuddin, N Dong, A Saha, W Hann, Y Wang, R Treitman, A Maraj, S Tolu, T Ollila, C Abeyakoon, V Calvert, A Ayers, A Hilali, I Trutzer, S Monick, J Sharp, H Tun, N Ghosh, G P Collins, V Deshani, J Can, A Kallam, B Kahl, J Chavez, K Cwynarski, J P Alderuccio (2025). 339 | Outcomes In An International Multicentre Study Of 600 Patients With CNS Relapse Of Large B Cell Lymphoma: Compartment Of Relapse Is Prognostic. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025 [Abstract]. 43(S3).
    3. P Stephan, K L Chohan, R A Redd, S Ahmed, C R Flowers, A Chauhan, A A Ayers, G Shouse, S K Thiruvengadam, A F Herrera, A M Bock, N Epperla, S M Buckley, B Hu, M A Lunning, G Salles, L Falchi, Y Sawalha, S Godbole, A P Jallouk, S T Bhaskar, P Armand, R W Merryman, J L Crombie, A V Danilov (2025). 243 | Real‐World Outcomes Of Cd20xcd3 Bispecific Antibody Therapy In Adult Patients With Relapsed/Refractory Transformed Indolent Lymphoma. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025 [Abstract]. 43(S3).
    4. K Kim, X Sun, T Voorhees, Y Youssef, N Epperla, M De Castro, K Ow, M Santiago, J Varghese, A Ayers, M Hawkins, V Leautaud, J Ramdial, P Kebriaei, E Shpall, H Liu, M Jain, J Chavez, F Locke, N Sattva, S Ahmed, S Paolo (2025). 456 | Identification Of An Optimal Absolute Lymphocyte Count Before Leukapheresis In Large B‐Cell Lymphoma Patients Treated With Cart. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025 [Abstract]. 43(S3).
    5. A M Bock, K Baron, C Wagner, L Fitzgerald, D Ermann, B Hu, H Shah, J Zak, N Epperla (2025). 504 | Impact Of The Neutrophil/Lymphocyte Ratio On Outcomes Following Bispecific Antibody Therapy In Relapsed/Refractory Lymphoma Patients. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025 [Abstract]. 43(S3).
    6. Baron K, Wagner C, Fitzgerald LA, Ermann DA, Hu B, Epperla N, Shah HA and Bock A 2025 (2025). 620 | A Standardized Process For A Rapid Dose Escalation Of Epcoritamab For Patients With Lymphoid Malignancies In The United States. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025 [Abstract]. 43(S3).
    7. A M Bock, L Feng, A Ayers, A Chauhan, S Thiruvengadam, A Jallouk, C DAngelo, Y Sawalha, S Godbole, R Merryman, S Bhaskar, K Baron, M Lunning, A Herrera, J L Crombie, N Epperla, S Ahmed (2025). 667 | Real‐World Safety And Efficacy Of Epcoritamab For Patients With Relapsed/Refractory Large B‐Cell Lymphomas. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025 [Abstract]. 43(S3).
    8. G Shouse, S Ahmed, L Chen, G Salles, A M Bock, M A Lunning, S Godbole, Y Sawalha, A A Ayers, S Thiruvengadam, C Goth, C R Flowers, A Chauhan, N Epperla, A Herrera, A V Danilov, L Falchi (2025). 671 | Glofitamab For The Treatment Of Relapsed/Refractory Diffuse Large B Cell Lymphoma, A Real‐World Evidence Study From The Cubic Consortium. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025 [Abstract]. 43(S3).
    9. A Jallouk, L Feng, A Ayers, A Chauhan, S Thiruvengadam, A Bock, S Bhaskar, N Epperla, A Herrera, S Ahmed (2025). 566 | Real-World Outcomes Of Mosunetuzumab Use From The Cubic Consortium. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025 [Abstract]. 43(S3).
    10. N Epperla, B Adedokun, H Hashmi, M Shadman, AM Winter, AF Herrera, M Hamadani, C Jacobson, N Ahmed, W Perez, Z Feng, K Hu, B Du, J Kim, T Best, A Baer, A Pradhan, MC Pasquini, and S Ahmed (2025). Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory (R/R) secondary central nervous system lymphoma (SCNSL). 2025 ASCO Annual Meeting, Chicago, IL [Abstract]. 43(16_Supplement).
    11. MJ Cortese, MM Herr, NM Nair, JT Romancik, DM Stephens, R Bhansali, TK Moyo, VP Kenkre, T Ollila, BT Hess, L Fitzgerald, G Shouse, M Matasar, J Davis, C Jesme, A Pelcovits, J Moreira, AY Lin, S Ma, J Winter, AV Danilov, NN Shah, SK Barta, JB Cohen, LI Gordon, N Epperla, N Grover, R Karmali (2025). Clinical Outcomes of Transformed Marginal Zone Lymphoma and Richter Transformation with CAR T-Cell Therapy: A US Multicenter Real-World Analysis. Abstracts from the 2025 Tandem Meetings of ASTCT and CIBMTR, February 2025, Honolulu, Hawaii [Abstract]. 31(2 (Supplement)), S224-S225.
    12. Matthew J Cortese, Megan M Herr, Nisha Nair, Jason Romancik, Natalie Grover, Rahul S Bhansali, Colin Thomas, Tamara K Moyo, Vaishalee P Kenkre, Thomas Ollila, Brian Hess, Lindsey Fitzgerald, Geoffrey Shouse, Matthew Matasar, Kaitlin Annunzio, James A Davis, Christy Jesme, Ari Pelcovits, Megan Melody, Jonathan Moreira, Adam Yuh Lin, Shuo Ma, Jane N Winter, Alex Niu, Alexey V Danilov, Nirav N Shah, Deborah M Stephens, Jonathon B Cohen, Leo I Gordon, Stefan K Barta, Narendranath Epperla, Reem Karmali (2024). Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis. American Society of Hematology (ASH Publication). [Abstract]. (2024) 144 (Supplement 1)(525).
    13. Megan Melody, Natalie Grover, Stephanie Franco, Jason T Romancik, Matthew J Cortese, Tamara K Moyo, Rahul S Bhansali, Thomas Ollila, Vaishalee P Kenkre, Lindsey Fitzgerald, Brian Hess, Matthew Matasar, Geoffrey Shouse, Kaitlin Annunzio, Megan M Herr, James A Davis, Christy Jesme, Ari Pelcovits, Jonathan Moreira, Shuo Ma, Jane N Winter, Adam Yuh Lin, Alexey Danilov, Ishan Roy, Stefan K Barta, Leo I Gordon, Deborah M Stephens, Jonathon B Cohen, Narendranath Epperla, Reem Karmali (2024). Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma. American Society of Hematology (ASH Publication). [Abstract]. (2024) 144 (Supplement 1)(473).
    14. Brandon L Ellsworth, Megan Melody, Narendranath Epperla, Natalie Grover, Jason T Romancik, Matthew J Cortese, Rahul S Bhansali, Tamara K Moyo, Vaishalee P Kenkre, Thomas Ollila, Brian Hess, Lindsey Fitzgerald, Geoffrey Shouse, Matthew Matasar, Kaitlin Annunzio, Megan M Herr, James A Davis, Christy Jesme, Ari Pelcovits, Jonathan Moreira, Adam Yuh Lin, Shuo Ma, Jane N Winter, Alexey V Danilov, Nirav N Shah, Stefan K Barta, Jonathon B Cohen, Leo I Gordon, Deborah M Stephens, Reem Karmali (2024). Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy. American Society of Hematology (ASH Publication). [Abstract]. (2024) 144 (Supplement 1)(612).
    15. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen A, Fenske T (2019). Post-relapse survival in Diffuse Large B-cell Lymphoma patients after experiencing therapy failure following autologous hematopoietic cell transplantation [Abstract]. 25(3), S22.
    16. Romancki J, Switchenko J, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson J, Barta SK, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Swalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen J (2019). The Impact of Pre-Diagnosis Tobacco use in Mantle Cell Lymphoma [Abstract]. 134(Suppll 1), 5891.
    17. Maddocks K, Awan F, Huang Y, Ayyappan S, Baiocchi R, Epperla N, Jaglowski S, William B, Blum K, Christian B (2018). Preliminary results of a phase I study of Obinutuzumab, venetoclax and lenalidomide in relapsed and refractory B-cell non-Hodgkin lymphoma [Abstract]. 132(Suppl 1), 4185.

    Video/Film/CD/Web/Podcast

    1. Epperla N (2024). Dr. Epperla on analyzing outcomes of tafasitamab for the treatment of R/R DLBCL among racial and ethnic minorities: Real-world data results [Web]. Available: hmpgloballearningnetwork.com.
    2. Epperla N (2024). Dr. Epperla on spotlight on follicular lymphoma therapies: Highlights from ASH 2024 [Web]. Cancer Therapy Advisor. Available: https://www.cancertherapyadvisor.com/cch/follicular-lymphoma-ash-2024-epcoritamab-mosunetuzumab/.
    3. Epperla N (2024). Dr. Epperla on new and emerging treatment options for follicular lymphoma [Web]. Available: https://www.cancertherapyadvisor.com/cch/follicular-lymphoma-car-t-bispecific-antibodies-epcoritamab-mosunetuzumab/.
    4. Epperla N (2023). Dr. Epperla on Impact of Large Cells and Ki-67% on Outcomes in Patients With Newly Diagnosed MZL [Web]. Available: https://www.vumedi.com/channel/insights-from-2023-ash-annual-meeting/.
    5. Epperla N (2023). Dr. Epperla on assessing the optimal Ki-67 cut-off for outcomes prediction among patients with newly diagnosed mantle cell lymphoma: Pooled Analysis from the CALGB50403 (Alliance) and MCL Real-World study cohort [Web]. Available: hmpgloballearningnetwork.com.
    6. Epperla N (2023). Dr. Epperla on exploring the role of FGFR1 as a therapeutic target among patients with MCL [Web]. Available: hmpgloballearningnetwork.com.
    7. Epperla N (2023). Dr. Epperla on ASTCT Recommendations for Transplantation and Cellular Therapies in DLBCL [Video]. Available: https://www.vumedi.com/video/astct-recommendations-for-transplantation-cellular-therapies-in-dlbcl/.
    8. Epperla N (2023). Dr. Epperla on promising prognostic value of diagnosis to treatment interval among patients with newly diagnosed mantle cell lymphoma [Web]. Available: hmpgloballearningnetwork.com.
    9. Epperla N (2023). Dr. Epperla and Dr. Andritsos on gender and patient outcomes in HCL using HCL patient data registry [Web]. Available: https://www.hairycellleukemia.org/calendar/2023/3/15/webinar-gender-and-patient-outcomes-an-hcl-patient-data-registry-analysis.
    10. Epperla N (2023). Dr. Epperla on High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series [Video]. Available: https://www.vumedi.com/video/ash-2022-high-grade-b-cell-lymphoma-not-otherwise-specified-cns-involvement-prophylaxis-and-recurren/?token=0da8ae69-fc9a-4c1d-aac4-e26f1cedc7e2&link_data=eyJiZXRfbWFpbF9pdGVtX2lkIjoxNjg1MTYzNzksImJldF9tYWlsX2FjdGlvbiI6ImJjIn0%3A1pUoo6%3Azp5EMyl3hue6UfytTpy_x-MCvgysc4bBYj1XipdF49k.
    11. Epperla N (2023). Dr. Epperla on how robust is POD24 as a predictor of survival in indolent lymphomas? [Video]. Available: https://lymphomahub.com/medical-information/how-robust-is-pod24-as-a-predictor-of-survival-in-indolent-lymphomas.
    12. Epperla N (2022). MCL: ibrutinib could become the ‘new standard’ [Web]. Available: https://www.medscape.com/s/viewarticle/985490?icd=login_success_email_match_norm.
    13. Epperla N (2022). Dr. Epperla on the prognostic outlook for patients with double-hit lymphoma. How does the prognostic outlook for patients with double-hit lymphoma impact disease management?  [Video]. Available: https://lymphomahub.com/medical-information/how-does-the-prognostic-outlook-for-patients-with-double-hit-lymphoma-impact-disease-management.
    14. Epperla N (2022). Dr. Epperla on BTK inhibitors in R/R MZL. MedEd On The Go - BTKs in B-Cell Lymphomas: Current Challenges and Emerging Solutions [Web]. Available: https://mededonthego.com/.
    15. Epperla N (2021). Incorporating novel agents into classical Hodgkin lymphoma treatment [Web]. Available: https://ashpublications.org/ashclinicalnews/news/1470/Incorporating-Novel-Agents-Into-Classical-Hodgkin?searchresult=1.
    16. Epperla N (2021). Dr. Epperla on the efficacy of brexucabtagene autoleucel in patients with mantle cell lymphoma [Video]. Available: https://www.onclive.com/view/dr-epperla-on-the-efficacy-of-brexucabtagene-autoleucel-in-mcl.
    17. Epperla N (2021). Dr. Epperla on Future Research Efforts in MCL [Video]. Available: https://www.onclive.com/view/dr-epperla-on-future-research-efforts-in-mcl.
    18. Epperla N (2021). Dr. Epperla on the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia   [Video]. Available: https://www.onclive.com/view/dr-epperla-on-the-implications-of-an-fda-approval-for-ublituximab-umbralisib-in-cll.
    19. Epperla N (2021). Epperla Elucidates on Excitement With Tafasitamab and Selinexor in DLBCL. Dr. Epperla expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and  other options in the pipeline.   [Web]. Available: https://www.onclive.com/view/epperla-elucidates-on-excitement-with-tafasitamab-and-selinexor-in-dlbcl.
    20. Epperla N (2020). Targeted therapies may alter the landscape of MCL treatment [Web]. Hematology News. Available: https://rarediseases.org/wp-content/uploads/2021/01/rare_diseases_cancers_2020-full.pdf.
    21. Epperla N (2020). Novel Regimens Generate Excitement in Lymphoma Treatment Paradigms. Dr. Epperla reflects on recent advances in Hodgkin lymphoma and non-Hodgkin lymphoma. [Web]. Available: https://www.onclive.com/view/novel-regimens-generate-excitement-in-lymphoma-treatment-paradigms.
    22. Epperla N (2017). Dr. Epperla on FDA approval of frontline Obinutuzumab in Follicular Lymphoma [Video]. Available: https://www.onclive.com/onclive-tv/dr-epperla-on-fda-approval-of-frontline-obinutuzumab-in-follicular-lymphoma.
    23. Epperla N (2017). Dr. Epperla on CAR T-cell therapy in MCL [Video]. Available: https://www.onclive.com/onclive-tv/dr-epperla-on-car-tcell-therapy-in-mcl.
    24. Epperla N (2017). Dr. Epperla on treatment following ibrutinib in MCL [Video]. Available: https://www.onclive.com/onclive-tv/dr-epperla-on-treatment-following-ibrutinib-in-mcl.
    25. Epperla N (2017). Dr. Epperla discusses the current treatment of MCL [Video]. Available: https://www.onclive.com/view/dr-epperla-discusses-the-current-treatment-of-mcl.
    26. Epperla N (2017). Adding rituximab to reduced intensity conditioning boosts PFS [Web]. MDedge. Available: https://www.mdedge.com/hematology-oncology/article/132533/aggressive-lymphomas/adding-rituximab-reduced-intensity.
    27. Epperla N (2017). Routine imaging does not significantly improve OS in relapsed DLBCL [Web]. Healio. Available: https://www.healio.com/news/hematology-oncology/20170214/routine-imaging-does-not-significantly-improve-os-in-relapsed-dlbcl.